发明名称 |
Methods of treatment using CTLA4 mutant molecules |
摘要 |
The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
|
申请公布号 |
US7439230(B2) |
申请公布日期 |
2008.10.21 |
申请号 |
US20040980742 |
申请日期 |
2004.11.03 |
申请人 |
BRISTOL-MYERS SQUIBB COMPANY |
发明人 |
PEACH ROBERT J.;NAEMURA JOSEPH R.;LINSLEY PETER S.;BAJORATH JURGEN |
分类号 |
A61K38/16;A61K38/00;A61K38/17;A61K39/00;A61K39/395;C07H21/04;C07K14/00;C07K14/705;C07K14/725;C07K14/74;C07K16/46;C12N5/0783;C12N15/09 |
主分类号 |
A61K38/16 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|